CDK1 and triple-negative breast carcinoma: In Myc-overexpressing triple-negative breast cancer (TNBC) xenografts, inhibition of cyclin-dependent kinase 1 (CDK1) with dinaciclib leads to synthetic lethality and attenuates distant metastasis.